We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Owen Mumford

Owen Mumford Ltd. is an industry leader in the medical device market with a diverse product range including advanced ... read more Featured Products: More products

Download Mobile App





Owen Mumford Presents Cutting-Edge Capillary Blood Sampling Devices for POC Testing

By LabMedica International staff writers
Posted on 15 Nov 2022
Print article
Image: Unistik Touch safety lancet is designed for seamless capillary blood sampling (Photo courtesy of Owen Mumford)
Image: Unistik Touch safety lancet is designed for seamless capillary blood sampling (Photo courtesy of Owen Mumford)

Owen Mumford (Oxford, UK) is once again exhibiting at this year’s MEDICA in Düsseldorf, Germany where it is presenting tomorrow’s medical device technology today. Attracting several thousand exhibitors from more than 50 countries, MEDICA is the world’s largest event for the medical sector, where each year, leading individuals from the fields of business, research, and politics converge alongside tens of thousands of decision-makers.

At MEDICA 2022, Owen Mumford is showcasing its pioneering products from three different ranges: safety pen needles, venous blood collection set and capillary blood sampling devices. The company’s portfolio of safety pen needles for insulin injections includes the Unifine SafeControl device which is designed to protect healthcare professionals, balancing both safety and control during the injection process. Compatible with all major brands of injection pens, it is available in a variety of sizes and features a manual push tab for easy, one-handed activation of the safety mechanism. It has both a visual and audible confirmation that the safety mechanism has been activated, making it a dual safety pen needle.

Among Owen Mumford’s featured products at MEDICA is its Unistik Touch safety lancet featuring ground-breaking comfort zone technology which helps to minimize the pain of capillary blood sampling. Unistik Touch safety lancet is designed to make capillary sampling as simple and seamless as possible. With one-touch activation, users can simply press the device against the sample site, allowing it to activate automatically under pressure. Once activated, the needle retracts into the body of the device, minimizing the risk of re-use, cross-infection and injury. At MEDICA 2022, Owen Mumford is also showcasing its recently launched venous blood collection portfolio consisting of new devices such as, the Unistik ShieldLock and Unistik VacuFlip. This range provides safety, comfort and quality for healthcare professionals when performing venous blood collection procedures.

Related Links:
Owen Mumford 

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Myeloperoxidase Assay
IDK MPO ELISA
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac

Print article

Channels

Clinical Chemistry

view channel
Image: The study demonstrated that electric-field molecular fingerprinting can probe cancer (Photo courtesy of ACS Central Science, 2025, 10.1021/acscentsci.4c02164)

New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma

Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read more

Molecular Diagnostics

view channel
Image: The study validated the Lumipulse p-tau21 automated and scalable blood test system (Photo courtesy of Fujirebio)

Blood Test for Early Alzheimer's Detection Achieves Over 90% Accuracy

Alzheimer's disease (AD) is a debilitating condition and a leading cause of disability and death worldwide. The availability of reliable diagnostic tools is currently restricted, and diagnosis often relies... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.